Informations for shareholders

Basic informations

The company is operating under the name Bioceltix (registered EU trademark). The company is operating in the form of a joint-stock company.

The company is located at Bierutowska 57-59 Str., 51-317 Wrocław, Poland.

The company is registered in the Register of Entrepreneurs of the National Court Register under KRS number 0000744521, District Court for Wrocław-Fabryczna in Wroclaw, VI Commercial Division of the National Court Register.

The statutory capital of the company amounts to PLN 244.401,40, paid in statutory capital amounts to PLN 244.401,40.

Tax identification number (NIP): PL899-27-94-360.

Statistical number (REGON): 364963245.

The quantity of all shares totals to 2.444.014, including series A shares in the amount of 1.981.500, series B shares in the amount of 104.290, series C shares in the amount of 172.000, series D shares in the amount of 186.224. The company’s shares are not privileged.

 

 

Shareholders structure:

Notifications for shareholders

  • On July 8, 2020, the Management Board of Bioceltix JSC with its seat in Wrocław, KRS: 0000744521 (hereinafter the “Company”) notifies the Shareholders that it convenes the Ordinary General Meeting on July 30, 2020 at 10:00. The Ordinary General Meeting will be held at the Notary’s Office Warczak-Mańdziak & Janicka, ul. Gwiaździsta 64 lok. 28/1, 28th floor, 53-413 Wrocław, with the following agenda:
    1. Opening of the session and election of the Chairman of the Ordinary General Meeting;
    2. Confirmation that the Annual General Meeting has been properly held and is able to adopt binding resolutions;
    3. Adoption of the agenda;
    4. Familiarization with the report of the Supervisory Board of the Company on the assessment of the financial statements, the report on the activities and the Management Board’s proposal to cover the loss for the financial year 2019;
    5. Consideration and approval of the Management Board’s report on the Company’s operations and the financial statements for the financial year 2019;
    6. Adoption of a resolution on coverage of the loss for the financial year 2019;
    7. Granting a vote of approval to the members of the Company’s governing bodies for the performance of their duties;
    8. Adoption of a resolution on the selection of the entity keeping the Register of the Company’s Shareholders;
    9. Free applications; 10. Closing the meeting.
  • The Management Board of Bioceltix JSC informs, that on June 9th, 2020 the information was received about the registration on June 2nd, 2020 in the National Court Register by the District Court for Wrocław-Fabryczna in Wrocław, VI Commercial Department of the National Court Register, of increase in the statutory capital of Bioceltix S.A. from PLN 243.460,80 to PLN 244.401,40 in connection with the additional issue of series D shares within the authorized capital. Due to the change, the number of registered series D shares increased from 176.818 to 186.224 shares.
  • The Management Board of Bioceltix JSC informs, that on March 3, 2020 the information was received about the registration on February 27, 2020 in the National Court Register by the District Court for Wrocław-Fabryczna in Wrocław, VI Commercial Department of the National Court Register, of increase in the statutory capital of Bioceltix S.A. from PLN 233.499,00 to PLN 243.460,80 in connection with the additional issue of series D shares within the authorized capital. Due to the change, the number of registered series D shares increased from 77.200 to 176.818 shares.